DOCSLIB.ORG

( 12 ) United States Patent

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
( 12 ) United States Patent US009993471B2 (12 ) United States Patent ( 10 ) Patent No. : US 9 , 993 ,471 B2 Abelson et al. (45 ) Date of Patent : * Jun. 12 , 2018 ( 54 ) OPHTHALMIC FORMULATIONS OF ( 56 ) References Cited CETIRIZINE AND METHODS OF USE U . S . PATENT DOCUMENTS @(71 ) Applicant : Nicox Ophthalmics, Inc. , Fort Worth , 4 , 407 , 791 A 10 / 1983 Stark TX (US ) 4 ,525 , 358 A 6 / 1985 Baltes et al . 5 , 188 , 826 A 2 / 1993 Chandrasekaran et al. @(72 ) Inventors : Mark Barry Abelson , Andover , MA 5 , 419 , 898 A 5 / 1995 Ikejiri et al . (US ) ; Matthew J . Chapin , Amesbury , 5 ,698 , 558 A 12 / 1997 Gray 6 , 103 ,735 A 8 / 2000 Aslanian et al . MA (US ) ; Paul Gomes , Andover , MA 6 , 436 , 924 B2 8 /2002 Poppe et al. (US ) ; George Minno , Windham , NH 6 , 649 , 602 B1 . 11/ 2003 Yanni (US ) ; Jackie Nice , Medford , MA (US ) 6 , 827 , 946 B2 12 / 2004 Hirsh 2002 / 0037297 A1 3 /2002 Crespo et al. @( 73 ) Assignee : NICOX OPHTHALMICS , INC ., Fort 2004 /0198743 Al 10 /2004 Hey et al. 2004 / 0198828 A1 10 / 2004 Abelson et al. Worth , TX (US ) 2005 /0239745 Al 10 /2005 Abelson et al . 2006 / 0025391A 2 / 2006 Lulla et al. @( * ) Notice : Subject to any disclaimer , the term of this 2006 /0183698 A1 8 / 2006 Abelson patent is extended or adjusted under 35 2006 / 0216353 A1 9 /2006 Liversidge et al. U . S . C . 154 ( b ) by 0 days. days . 2006 / 0228306 AL 10 / 2006 Lane 2006 / 0263350 A1 11/ 2006 Lane This patent is subject to a terminal dis 2007 /0020330 AL 1 / 2007 Dang et al. claimer . 2007 / 0275974 A1 11/ 2007 Fanara et al . 2008 /0085922 A14 / 2008 Raja et al. (21 ) Appl. No. : 15/ 456 ,249 2008 /0254029 A1 10 / 2008 Yani et al. ( 22 ) Filed : Mar . 10 , 2017 FOREIGN PATENT DOCUMENTS FP 0433766 A1 6 / 1991 (65 ) Prior Publication Data EP 0920315 B1 . 6 / 1999 JP 6 - 239748 8 / 1994 US 2017 /0182035 A1 Jun . 29, 2017 JP 2009 -507009 2 / 2009 RU 2220740 C1 1 / 2004 Related U . S . Application Data WO WO 97 /46243 A112 / 1997 WO WO 98 / 06394 A1 2 / 1998 (63 ) Continuation of application No . 14 / 982 , 258 , filed on wo WO 99 / 15203 Al 4 / 1999 Dec . 29 , 2015 , now Pat . No. 9 ,750 ,684 , which is a wo WO 03 /049770 A1 6 / 2003 continuation of application No. 12 / 724 , 128 , filed on WO WO 04 / 066960 A2 8 /2004 Mar . 15 , 2010 , now Pat . No . 9 ,254 ,286 . WO WO 04 /069338 Al 8 / 2004 WO WO 05 /030331 Al 4 / 2005 (60 ) Provisional application No. 61 / 161, 006 , filed on Mar. WO WO 05 / 107711 A2 11 / 2005 17 , 2009, provisional application No. 61 / 174 ,850 , WO WO 06 / 102494 A2 9 /2006 WO WO 2007 /026151 A1 3 / 2007 filed on May 1 , 2009 . WO WO 07 / 117971 A2 10 /2007 (51 ) Int. CI. A61K 31/ 56 ( 2006 .01 ) OTHER PUBLICATIONS A61K 31/ 495 ( 2006 .01 ) Abelson et al. , “ A Randomized , Double - Blind , Parallel -Group A61K 31 /569 ( 2006 .01 ) Comparison of Olopatadine 0 . 1 % Ophthalmic Solution Versus A61K 31 /4965 ( 2006 .01 ) Placebo for Controlling the Signs and Symptoms of Seasonal A61K 9 / 00 ( 2006 .01 ) Allergic Conjuctivitis and Rhinoconjunctivitis ” , Clinical Therapeu A61K 9 / 08 ( 2006 .01 ) A61K 31/ 4174 ( 2006 .01 ) tics , 25 ( 3 ) : 931 -947 ( 2003 ) . A61K 47 / 10 ( 2017 . 01 ) (Continued ) A61K 47 / 18 ( 2017 .01 ) A61K 47/ 02 ( 2006 .01 ) Primary Examiner — Zohreh A Fay A61K 47 / 26 ( 2006 .01 ) ( 74 ) Attorney, Agent, or Firm — Arent Fox LLP A61K 47 /38 ( 2006 .01 ) ( 52 ) U . S . CI. (57 ) ABSTRACT CPC .. .. A61K 31 /495 (2013 . 01 ) ; A61K 9 /0048 ( 2013 .01 ) ; A61K 9 / 08 (2013 .01 ) ; A61K The present invention provides stable topical formulations 31/ 4174 ( 2013 . 01 ) ; A61K 31/ 4965 ( 2013 .01 ) ; of cetirizine that provide a comfortable formulation when A61K 31 / 56 ( 2013 .01 ) ; A61K 31 /569 instilled in the eye and is effective in the treatment of allergic ( 2013 . 01 ) ; A61K 47 /02 (2013 . 01 ) ; A61K 47 / 10 conjunctivitis and /or allergic conjunctivitis . The invention (2013 .01 ) ; A61K 47 / 183 ( 2013 .01 ) ; A61K further provides methods of treating allergic conjunctivitis 47 / 186 ( 2013 . 01 ) ; A61K 47 / 26 (2013 . 01) ; and /or allergic rhinoconjunctivitis in a subject in need of A61K 4738 ( 2013 . 01 ) such treatment by topical application of the cetirizine for (58 ) Field of Classification Search mulations of the invention directly to the eye . CPC combination set ( s ) only . See application file for complete search history . 6 Claims, 31 Drawing Sheets US 9 ,993 ,471 B2 Page 2 References Cited Berger et al . , “ Effects of adjuvant therapy with 0 . 1 % olopatadine ( 56 ) hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy ” , Ann . Allergy Asthma Immunol, 95 ( 4 ) : 361 -37112005 ) . OTHER PUBLICATIONS Lanier et al. , Comparison of the Efficacy of Combined Fluticasone Crampton et al. , “ A Comparison of the Relative Clinical Efficacy of Propionate and Olopatadine Versus Combined Fluticasone Propionate and Fexofenadine for the treatment of Allergic a Single Dose of Ketotifen Fumarate 0 /025 % Ophthalmic Solution Rhinoconjunctivitis Induced by Conjunctival Allergen Challenge , Versus Placebo in Inhibiting the Signs and Symptoms of Allergic Clin . Ther ., 24 ( 7 ) : 1161 - 1174 ( 2002 ) . Rhinoconjunctivitis as Induced by the Conjunctival Allergen Chal Ousler et al ., “ An evaluation of the ocular drying effects of 2 lenge Model ” , Clinical Therapeutics , 24 ( 11 ) : 1800 - 1808 ( 2002 ) . systemic antihistamines : loratadine and cetirizine hydrochloride ” , Goodman and Gilman ' s the Pharmacological Basis of Therapeutics Ann . Allergy Asthma Immunol. , 93 ( 5 ) : 460 - 464 ( 2004 ) . ( Tenth Edition ) (2001 ) , McGraw Hill , Chapter 1 , pp . 3 - 29 . Spangler et al ., “ Randomized , Double -Masked Comparison of United States Pharmacopeia (http :/ /en .wikipedia . org /wiki / Olopatadine Ophthalmic Solution , Mometasone Furoate United States Pharmacopeia # Product_ quality. E2 . 80 . Monohydrate Nasal Spray, and Fexofenadine Hydrochloride Tablets 93standards _ and _ verification ) assessed from the internet on Oct . Using the Conjunctival and Nasal Allergen Challenge Models ” , 22 , 2012 Clin . Ther . , 25 ( 8 ) :2245 -2267 (2003 ) . U . S . Patent Jun . 12, 2018 Sheet 1 of 31 US 9 ,993 ,471 B2 * t VehicleN=16 w her ouse p *:Clinicallyandstatisticallysignificant(P<0.05)difference 35 Time(min)postCAC* * . * . * . * . * Post-Dose) *.Statisticallysignificant(P<005)difference RODRIOS Figure1A:AllergyHumanPOCStudy#1Results(OcularItching16Hoursw deparCetirizineN=15 WWWWWWWWWWWWWWWWWWWWWNanananananana . i News on 1 ) scale 4 - 0( Scores Itching Ocular Mean U . S . Patent Jun . 12, 2018 Sheet 2 of 31 US 9 ,993 ,471 B2 20 089929 1994 ogooc000990360og 15 9990000099/ Cetirizine0.1%N=15-Vehicle16 Time(min)post-CAC oogoo * gogsoo wwwwwwwwwwwwwwwwwwwwwwwWYNEwwwwwwwww7WWWWWWWWWWWW 7 S Figure1B:ConjunctivalRednessScoreswww hoor Baseline december u No svorite ) scale 4 - 0( Score RednessConjunctival Soooo goooo Mean U . S . Patent Jun . 12, 2018 Sheet 3 of 31 US 9 , 993, 471 B2 VehicleN=16+ AKKER 69692 XOO000000000000w annannnnnnnnnnnnnnnnn wwwwwwwww tion ! AnnaM wwwwwwwwwwwwwwwwwwwwwwwwcco wood Time(min)postinstillation! Figure2:AllergyHumanPOCStudy#1Results (DropComfort) CetirizineN=15atip *Statisticallysignificant(P<0.05)difference 000000 DOS songs99999000000 wwwwwwww 00000000000 wwwwwwwwwwwwwwwwwwwwwwwwwwwww Note:MostUncomfortableCommerciallyAvailableAllergyDrop=4K DOO L Senannnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn 3:3A o voo ONWAO ) scale 10- 0 ( Scores Comfort* Drop Mean 9 ??Uncomfortable VeryComfortable U . S . Patent Jun . 12, 2018 Sheet 4 of 31 US 9 ,993 ,471 B2 BeginQDdosing X Visit2B(Day0) mm )CACAV2from(w ConfirmationCAC om w t=8hours Figure3A:StudyDesignScreening Redness,ChemosisLidSwellingWateryEyesRhinorrheaNasalPruritis&Earorpalate Onlysubjectswhoexperiencedascoreof>2forocularitching,conjunctivalrednessand nasalcongestionatVisit1andascoreof>2forocularitchingconjunctivalrednessin ourof3timepointand>2fornasalcongestioninatleastout4pointsVisit2B ConfirmationCAC t=0 Ocularallergicassessments:Itching3,5and7minutespost-CAC PeakNasalInspiratoryFlow:9and30minutespost-CAC Visit1(Day-),2A0 - - - Pruritis:7,15and20minutespost-CAC werescheduledforVisit3 t=0 1 t CACTitration U . S . Patent Jun . 12, 2018 Sheet 5 of 31 US 9 ,993 ,471 B2 Visit4B(Day7) CAC t=8hours(fromV4A StudyMedication) onogpogon CAC t=0 Visit4A(Day7) CACpostminutes-7Itching3,5andassessments:Ocularallergic Redness,ChemosisLidSwellingWateryEyesRhinorrheaNasalPruritis& Figure3B:StudyDesignEfficacy 4 Evaluation Study t=-15min PeakNasalInspiratoryFlow:9and30minutespost-CAC Medication CACpostminutes-and2015,palatePruritis:7Earor XXXXXXXXXXXXXXXXXXXXXXXXX* XXXXXXXXXXXXXX* X CAC two Visit3(Day6) StudyMedication t=-15min U . S . Patent Jun . 12 , 2018 Sheet 6 of 31 US 9, 993, 471 B2 Vehicle(N=15) * SelinaF10.01%(N=15) Figure4:PrimaryOcularItching(Visit4B) +F10.005%(N=16) willigaF10.001%(N=16) scalew ) 4- 0( cing Ith Ocularco - Mean o U . S . Patent Jun . 12 , 2018 Sheet 7 of 31 US 9 ,993 ,471 B2 seteVehicle(N=15) Cine 75 0.01%(N=15) Figure5:PrimaryConjunctivalRedness(Visit4B) +-0.005%(N=16) * * *P<0,05Futicasone.005%vsVehicle;Fluticasone01 laF10.001%(N=16) *P<0.05Futicasone005%vsVehicle * scaleetu ) 4 - 0 (w Redness6 N Conjunctivalc Mean U . S . Patent Jun . 12, 2018 Sheet 8 of 31 US 9 , 993, 471 B2 Figure6:PrimaryLidSwelling(Visit4B) +-F10.005%(N=16)meitena0115_*Vehicle alikanF10.001%(N=16) *:P<0.05Fluticasone001%vsVehicle om a 1.5 scale ) 3 - 0 ( Swelling Lid Mean& U . S . Patent Jun . 12, 2018 Sheet 9 of 31 US 9 , 993 , 471 B2 *Vehicle(N=15) 20 »F10.01%(N=15) Figure7:PrimaryNasalCongestion(Visit4B)
Load more

Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2001/0053775 A1 Seidel Et Al
    US 2001.0053775A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2001/0053775 A1 Seidel et al. 43) Pub. Date: Dec. 20,9 2001 (54) NASAL SOLUTIONS (30) Foreign Application Priority Data (76) Inventors: Matthias Seidel, Ittigen (CH); Jan. 30, 1998 (EP)........................................ 9881OO69-9 Christopher Buckley, Commugny (CH) Publication Classification Correspondence Address: RVNSporation (51) Int. Cl." ......................... A61K 31156; A61K 31/57; ENNINEMARK DEPT (52) U.S. Cl. ........................"I,...s. SUMMIT, NJ 079011027 (21) Appl. No.: 09/880,678 (57) ABSTRACT (22) Filed: Jun. 13, 2001 Related U.S. Application Data The invention relates to liquid pharmaceutical compositions adapted to nasal administration. The liquid nasal formula (63) Continuation of application No. 09/601,123, filed on tions of the invention are characterized inter alia by having Jul. 27, 2000. excellent and prolonged moisturizing properties. US 2001/0053775 A1 Dec. 20, 2001 NASAL SOLUTIONS embodiment of the invention they may also be present in a 0001. The present invention relates to pharmaceutical Slightly Viscous form, e.g. like a Syrup. However, they all compositions intended for nasal administration. More Spe can be clearly discriminated from nasal formulations in gel cifically, it concerns liquid nasal formulations with form in that they-in contrast to gels-are able to form improved moisturizing properties. drops and can be used as SprayS. 0014) Active substances suitable for nasal administration 0002 The nasal administration of active substances is a (a) are e.g. vasoconstrictors, e.g. Xylometazoline, e.g. widely used method of treatment. Active substances which Xylometazoline hydrochloride; indanazoline, metizoline; come into consideration are, for example, vasoconstrictors, naphazoline, e.g.
    [Show full text]
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST
    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
    [Show full text]
  • Review of Cough and Cold Medicines in Children Tabulated Summaries of Clinical Trials Prepared by the TGA to Accompany the Report by the External Reviewers
    Review of cough and cold medicines in children Tabulated summaries of clinical trials prepared by the TGA to accompany the Report by the External Reviewers May 2009 Contents Table A1: Dextromethorphan........................................................................................................2 Table A2: Codeine ........................................................................................................................5 Table A3: Pholcodine....................................................................................................................9 Table A4: Dihydrocodeine...........................................................................................................12 Table A5: Expectorants for acute cough in children ...................................................................13 Table A6: Antihistamine monotherapy for the common cold and acute cough in children..........15 Table A7: Antihistamine-decongestant combinations for the common cold and acute cough in children .......................................................................................................................................23 Table A8: Nasal decongestants for the common cold ................................................................27 Page 1 of 34 Address: PO Box 100 Woden ACT 2606 Website: www.tga.gov.au Telephone: 02 6232 8444 Facsimile: 02 6232 8605 ABN 40 939 406 804 Table A1: Dextromethorphan Reference Method Participants Interventions Outcomes 1. Smith, et al. Cochrane Review 25 studies between 8
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Use of Combinations Comprising Non-Sedating Antihistamines And
    Europaisches Patentamt (19) European Patent Office Office europeen des brevets (11) EP 0 903 151 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) int. CI 6: A61 K 45/06, A61K 31/55, 24.03.1999 Bulletin 1999/12 A61K 31/415 (21) Application number: 97116494.2 //(A61K31/55, 31:415) (22) Date of filing: 22.09.1997 (84) Designated Contracting States: (72) Inventors: AT BE CH DE DK ES Fl FR GB GR IE IT LI LU MC • Dr. Diez Crespo, Maria del Carmen NL PT SE 28043 Madrid (ES) Designated Extension States: • Dr.Mainardi, Roberto AL LT LV RO SI 05101-070 Sao Paulo - SP (BR) • Prof. Szelenyi, Istvan (71) Applicant: D-90571 Schwaig (DE) ASTA Medica Aktiengesellschaft • Dr. Muckenschnabel, Reinhard D-01 277 Dresden (DE) D-60388 Frankfurt (DE) (54) Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms (57) Pharmaceutical combination, applicable topi- cally, containing a non-sedating antihistamine in combi- nation with an a-adrenergic agonist and optionally conventional physiologically acceptable carriers, dilut- ing agents and auxiliaries substances for the prophy- laxis and treatment of allergic and/or vasomotoric rhinitis, conjunctivitis, cold, cold-like and/ or flu symp- toms are claimed. < LO CO o o Q_ LU Printed by Xerox (UK) Business Services 2.16.7/3.6 EP 0 903 151 A1 Description Technical field 5 [0001] The present invention relates generally to novel pharmaceutical compositions containing ..topical decongest- ants", preferably epinephrine, fenoxazoline, indanazoline, naphazoline, oxedrine, oxymetazoline, phenylephrine, tefazo- line, tetryzoline, tramazoline, tymazoline or xylometazoline and a non-sedating antihistamine, applicable topically such as levocabastine, ef letirizine, however preferably azelastine.
    [Show full text]
  • Modulation of Virulence Factors of Staphylococcus Aureus by Nasal Decongestants
    OPEN ACCESS Insight Microbiology ISSN 2041-0387 DOI: 10.5567/IMICRO-IK.2016.1.6 Research Article Modulation of Virulence Factors of Staphylococcus aureus by Nasal Decongestants Jefferson Celli Honorio, Cristina Rauen Ribas, Maria Fernanda Cordeiro Arruda, Luiz Fernado Bianchini, Patricia Maria Stuelp Campelo and Edvaldo Aatonio Ribeiro Rosa Xenobiotics Research Unit, School of Life Sciences, Pontifical Catholic University of Paraná, Brasil Abstract Background and Objective: When applied, nasal decongestants may reach cells of Staphylococcus aureus, a bacterium that commonly colonizes the mucosa. The aim of this study was to evaluate experimentally the effect of corticoids (budesonide, dexamethasone and triamcinolone), alpha-agonists (naphazoline, oxymetazoline, fenoxazoline and xylometazoline) on biofilm formation and secretion of staphylococcal haemolysin and proteases. Materials and Methods: Commercial formulations had their preservatives neutralized and were added to the culture broth in which the strain ATCC®25923™ was grown. The biofilm production was measured after 72 h of incubation. This study investigated the proteolytic and haemolytic activities of culture supernatant for the interval between the 48-72 h of incubation. Results: It was obtained that there are interactions amongst decongestants and S. aureus as biomass reductions (budesonide, triamcinolone and fenoxazoline), protease activity (triamcinolone), specific protease activity (triamcinolone), haemolytic index (budesonide, triamcinolone and dexamethasone) and specific
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Decongestants, Antihistamines and Nasal Irrigation for Acute Sinusitis in Children (Review)
    Decongestants, antihistamines and nasal irrigation for acute sinusitis in children (Review) Shaikh N, Wald ER This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2014, Issue 10 http://www.thecochranelibrary.com Decongestants, antihistamines and nasal irrigation for acute sinusitis in children (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 5 Figure1. ..................................... 6 DISCUSSION ..................................... 8 AUTHORS’CONCLUSIONS . 8 ACKNOWLEDGEMENTS . 8 REFERENCES ..................................... 8 CHARACTERISTICSOFSTUDIES . 12 DATAANDANALYSES. 14 APPENDICES ..................................... 14 WHAT’SNEW..................................... 17 HISTORY....................................... 17 CONTRIBUTIONSOFAUTHORS . 17 DECLARATIONSOFINTEREST . 17 SOURCESOFSUPPORT . 17 DIFFERENCES BETWEEN PROTOCOL AND REVIEW . .... 18 INDEXTERMS .................................... 18 Decongestants, antihistamines and nasal irrigation for acute sinusitis in children (Review) i Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention
    [Show full text]
  • Prohibited List 2021
    WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST 2021 This List shall come into effect on 1 January 2021. TABLE OF CONTENTS Please note that the list of examples of medical conditions below is not inclusive. SUBSTANCES & METHODS PROHIBITED AT ALL TIMES S0 Non-approved substances ..................................................................................4 S1 Anabolic agents ...................................................................................................5 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. male hypogonadism. S2 Peptide hormones, growth factors, related substances, and mimetics ...........7 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaemia, male hypogonadism, growth hormone deficiency. S3 Beta-2 agonists ...................................................................................................9 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. asthma and other respiratory disorders. S4 Hormone and metabolic modulators ...............................................................10 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. breast cancer, diabetes, infertility (female), polycystic ovarian syndrome. S5 Diuretics and masking agents ..........................................................................12 Some of these substance(s) may
    [Show full text]